HGF: dosing and handling
> Updated:
Calculate the HGF dose
Enter your dose and diluent volume for HGF — the calculator will do the rest.
Human dosing
HGF dosing (hepatocyte growth factor) in humans has been studied in only one early-phase clinical trial, so the schedule below is a narrow slice of the published clinical and preclinical data, not a standard for self-administration.
| Period / condition | Dose | Escalation |
|---|---|---|
| Phase I/II clinical (IV infusion ~3 h, daily 12–14 days) | 0.6 mg/m² per day | Only studied dose |
| Planned escalation in the same protocol | up to 1.2–2.4 mg/m² per day | Not reached in the trial |
| Preclinical reference (rats, SC / IM / IV) | 0.25–2.5 mg/kg | Preclinical data only |
Practical dosing and effect details
HGF is a large protein (hepatocyte growth factor), so oral intake is not considered for it: the digestive system breaks down proteins of this size before they can be absorbed. In the referenced Phase I/II trial it was given exclusively by intravenous infusion (about 3 hours) daily for 12-14 days. The dose here is set in mg/m² of body-surface area rather than fixed milligrams, a common approach for compounds with a narrow therapeutic window, where the load is matched to the patient's size. The planned escalation to 1.2-2.4 mg/m² per day was not reached in that trial, so the upper figure in the table remains theoretical rather than clinically confirmed. The preclinical rat data (0.25-2.5 mg/kg, SC, IM, or IV) cover a wider range of administration routes, but that is a different species, and it does not carry over to humans directly. This is reference information for planning a research protocol, not a medical recommendation and not instructions for self-administration.
Research protocols
HGF: reference regimens
Controlled data on this compound are limited.
HGF (hepatocyte growth factor) is a large protein administered parenterally in studies, mainly as an intravenous infusion; this is a generalized reference from the limited clinical and preclinical data.
More scientific background in the HGF monograph
Notes and safety
- • HGF is a research peptide. Human safety and efficacy data are limited.
- • The regimens shown are based on publications and research protocols, not clinical recommendations.
- • Individual reactions may vary. Published protocols typically start dosing at the lower end of the reported range.
- • Not recommended for use with chronic illness, pregnancy, or breastfeeding.
- • This information is for educational purposes and is not medical advice.
